Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study.

ABSTRACT:

Background

Cancer immunotherapy with immune checkpoint inhibitors (ICIs) is a pivotal treatment for cancers, including non-small cell lung cancer (NSCLC). ICIs are often associated with adverse events (AEs), including immune-related AEs (irAEs). Bojungikki-tang (BJIKT), a traditional herbal medicine, has immunomodulatory properties and may alleviate fatigue and inflammation in patients with advanced cancer.In this multicenter, randomized, placebo-controlled pilot trial, we evaluated the safety and potential effects of BJIKT on fatigue, muscle loss, and immune response in patients with advanced NSCLC undergoing atezolizumab monotherapy.

Methods

Twenty-eight patients were randomized to either the BJIKT (n = 14) or placebo (n = 14) groups. Primary outcomes included AEs and irAE

SUBMITTER: Ko MM 

PROVIDER: S-EPMC12306011 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature